Protocol Ledger

NCT03694522 · Phase II · COMPLETED

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Interventional Phase II clinical trial protocol NCT03694522 sponsored by Amgen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-09-14 Enrollment: 155 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03694522
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)155 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03694522
Protocol FieldVerified Registry Value
NCT IdentifierNCT03694522
Consolidated Lead SponsorAmgen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment155 participants (ACTUAL)
Registered Start Date2018-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI